BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10573204)

  • 1. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
    Sparreboom A; Planting AS; Jewell RC; van der Burg ME; van der Gaast A; de Bruijn P; Loos WJ; Nooter K; Chandler LH; Paul EM; Wissel PS; Verweij J
    Anticancer Drugs; 1999 Sep; 10(8):719-28. PubMed ID: 10573204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
    Booth CL; Brouwer KR; Brouwer KL
    Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.
    Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
    Pharm Res; 1998 Apr; 15(4):599-605. PubMed ID: 9587957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
    Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
    J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
    Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
    Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.
    Savolainen J; Edwards JE; Morgan ME; McNamara PJ; Anderson BD
    Drug Metab Dispos; 2002 May; 30(5):479-82. PubMed ID: 11950774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
    Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
    Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
    Germann UA; Ford PJ; Shlyakhter D; Mason VS; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):141-55. PubMed ID: 9073310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
    Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.
    Chen C; Pollack GM
    Pharm Res; 1999 Feb; 16(2):296-301. PubMed ID: 10100317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.
    Edwards JE; Brouwer KR; McNamara PJ
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2284-6. PubMed ID: 12069991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
    Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
    den Ouden D; van den Heuvel M; Schoester M; van Rens G; Sonneveld P
    Leukemia; 1996 Dec; 10(12):1930-6. PubMed ID: 8946933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
    de Bruijn P; Verweij J; Loos WJ; Kolker HJ; Planting AS; Nooter K; Stoter G; Sparreboom A
    Anal Biochem; 1999 Jan; 266(2):216-21. PubMed ID: 9888978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.
    Starling JJ; Shepard RL; Cao J; Law KL; Norman BH; Kroin JS; Ehlhardt WJ; Baughman TM; Winter MA; Bell MG; Shih C; Gruber J; Elmquist WF; Dantzig AH
    Adv Enzyme Regul; 1997; 37():335-47. PubMed ID: 9381979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.
    Warmann S; Göhring G; Teichmann B; Geerlings H; Fuchs J
    J Pediatr Surg; 2002 Nov; 37(11):1579-84. PubMed ID: 12407543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
    Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.